These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2924258)

  • 21. Enhancement of DNA damage in mammalian cells upon bioreduction of the nitroimidazole-aziridines RSU-1069 and RSU-1131.
    Jenner TJ; Sapora O; O'Neill P; Fielden EM
    Biochem Pharmacol; 1988 Oct; 37(20):3837-42. PubMed ID: 3190731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative study of thermoradiosensitization by misonidazole and metronidazole in vivo: antitumour effect and pharmacokinetics.
    Wong KH; Maezawa H; Urano M
    Int J Hyperthermia; 1992; 8(5):645-58. PubMed ID: 1402141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of nitroimidazole hypoxic cell radiosensitizers in a human tumor cell line high in intracellular glutathione.
    DeGraff WG; Russo A; Gamson J; Mitchell JB
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1021-4. PubMed ID: 2522917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxicity of RSU 1069 in spheroids and murine tumors.
    Olive PL; Durand RE; Chaplin DJ
    Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1361-6. PubMed ID: 3624045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin alpha-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069).
    Binger M; Workman P
    Cancer Chemother Pharmacol; 1991; 29(1):37-47. PubMed ID: 1742848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variation of the radiosensitizing efficiency of RSU-1069 with pre-irradiation contact times: a rapid mix study.
    Austen KR; Jenner TJ; O'Neill P; Fielden EM
    Int J Radiat Biol Relat Stud Phys Chem Med; 1987 Aug; 52(2):281-8. PubMed ID: 3497125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
    Chaplin DJ
    Radiat Res; 1988 Aug; 115(2):292-302. PubMed ID: 3406369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on the toxicity of RSU-1069.
    Whitmore GF; Gulyas S
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1219-22. PubMed ID: 3755716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical trials with hypoxic cell sensitizers: time to retrench or time to push forward?
    Urtasun RC; Coleman CN; Wasserman TH; Phillips TL
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1691-6. PubMed ID: 6237083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
    Siemann DW
    Br J Cancer; 1982 Feb; 45(2):272-81. PubMed ID: 6460517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicity of RSU-1069 for KHT cells treated in vivo or in vitro: evidence for a diffusible toxic product.
    Hill RP; Gulyas S; Whitmore GF
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1111-4. PubMed ID: 2703391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The repair of DNA damage induced in V79 mammalian cells by the nitroimidazole-aziridine, RSU-1069. Implications for radiosensitization.
    Jenner TJ; O'Neill P; Crump PW; Fielden EM; Sapora O; Santodonato L
    Biochem Pharmacol; 1991 Oct; 42(9):1705-10. PubMed ID: 1930296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo testing of a 2-nitroimidazole radiosensitizer (Ro 03-8799) using repeated administration.
    Williams MV; Denekamp J; Minchinton AI; Stratford MR
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):477-81. PubMed ID: 7107370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
    Chaplin DJ; Acker B
    Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):579-85. PubMed ID: 3558048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoxic cell radiosensitizers: expectations and progress in drug development.
    Coleman CN
    Int J Radiat Oncol Biol Phys; 1985 Feb; 11(2):323-9. PubMed ID: 3156109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic enhancement of the efficacy of the bioreductively activated alkylating agent RSU-1164 in the treatment of prostatic cancer by photodynamic therapy.
    Henry JM; Isaacs JT
    J Urol; 1989 Jul; 142(1):165-70. PubMed ID: 2733098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemosensitization of lomustine by misonidazole, benznidazole, and RSU 1069.
    Workman P
    Cancer Treat Rep; 1986 Sep; 70(9):1139-40. PubMed ID: 3755651
    [No Abstract]   [Full Text] [Related]  

  • 38. Combinations of radiation and misonidazole in a murine lung tumor model.
    Siemann DW; Kochanski K
    Radiat Res; 1981 May; 86(2):387-97. PubMed ID: 7232698
    [No Abstract]   [Full Text] [Related]  

  • 39. Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069.
    Siemann DW; Alliet K; Maddison K; Wolf K
    Cancer Treat Rep; 1985 Dec; 69(12):1409-14. PubMed ID: 3841024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiosensitization of tumors and normal tissues by combined treatment with misonidazole and heat.
    Hofer KG; MacKinnon AR; Schubert AL; Lehr JE; Grimmett EV
    Radiology; 1981 Dec; 141(3):801-9. PubMed ID: 7302238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.